We showed that cancer-associated NFIB overexpression provokes genetic alterations that mimic the genomic aberrations in breast carcinomas and that NFIB-evoked genomic abnormalities dynamically evolve to confer growth advantage and therapeutic resistance. This evidence concerns the gene NFIB and cancer.